Sino Biopharma Unit's Application for Analgesic Accepted in China
Sino Biopharmaceutical (HKG:1177) unit Beijing Tide Pharmaceutical's new drug application for ropivacaine hydrochloride sustained-release solution was accepted by China's National Medical Products Administration. The acceptance is for the drug as a postoperative long-acting analgesic in adults, according to a Friday Hong Kong bourse filing.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.